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Abstract
Angiogenesis plays a critical role in processes such as organ development, wound healing, and tumor growth. It requires
well-orchestrated integration of soluble and matrix factors and timely recognition of such signals to regulate this process.
Previous work has shown that newly forming vessels express the chemokine receptor CXC receptor 3 (CXCR3) and,
activation by its ligand IP-10 (CXCL10), both inhibits development of new vasculature and causes regression of newly
formed vessels. To identify and develop new therapeutic agents to limit or reverse pathological angiogenesis, we identified
a 21 amino acid fragment of IP-10, spanning the a-helical domain residues 77–98, that mimic the actions of the whole IP-10
molecule on endothelial cells. Treatment of the endothelial cells with the 22 amino acid fragment referred to as IP-10p
significantly inhibited VEGF-induced endothelial motility and tube formation in vitro, properties critical for angiogenesis.
Using a Matrigel plug assay in vivo, we demonstrate that IP-10p both prevented vessel formation and induced involution of
nascent vessels. CXCR3 neutralizing antibody was able to block the inhibitory effects of the IP-10p, demonstrating specificity
of the peptide. Inhibition of endothelial function by IP-10p was similar to that described for IP-10, secondary to CXCR3-
mediated increase in cAMP production, activation of PKA inhibiting cell migration, and inhibition of VEGF-mediated m-
calpain activation. IP-10p provides a novel therapeutic agent that inhibits endothelial cell function thus, allowing for the
modulation of angiogenesis.
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Introduction
The formation of new blood vessels, whether by angiogenesis
or vasculogenesis, is critical for several physiological processes
including embryogenesis, organogenesis and vascular remodeling.
Angiogenesis is regulated by a complex and interrelated system
of pathways that involve various angiogenic and angiostatic
factors [1,2]. Over- or under- expression of these factors results
in pathologic conditions, as noted for excessive angiogenesis in
tumors, or untimely termination of angiogenesis that results in
unhealed chronic wounds [3]. Researchers have sought to better
understand the signaling pathways of these angiogenesis regula-
tors to provide new therapies to modulate these and other
pathological conditions.
Recent evidence demonstrates that members of the CXC
chemokine family can act as either angiogenic or angiostatic
factors, depending on the presence of the ELR (Glu-Leu-Arg)
motif in their NH2 terminus [1]. Among this family, the
chemokines (IP-9/ITAC (CXCL11) IP-10 (CXCL10), MIG
(CXCL9) and CXCL4 (PF4) lack the canonical N-terminal ELR
sequence [4] and bind in common to the ubiquitous CXCR3
chemokine receptor. CXCR3 has two isoforms CXCR3-A and
CXCR3-B. Recent studies have shown that CXCR3 isoforms
differentially regulate cell function. Activation of CXCR3-A has
been shown to induce chemotaxis and proliferation in various cells
types [5,6]. Alternatively, CXCR3-B activation inhibits migration
and proliferation and induces apoptosis [6,7,8]. In addition, IP-10
and PF4 have been reported to be angiostatic and have anti-tumor
activity via its signaling through CXCR3 [7,9,10].
IP-10 is secreted by a diverse spectrum of cells in many tissues,
and displays pleiotrophic effects in immunity, angiogenesis, and
organ-specific metastases of cancer, making it a promising
therapeutic target for a wide variety of diseases. To develop IP-
10 as a therapeutic agent, structural details of its mechanism of
action are needed to understand its role in the aforementioned
pathological conditions. It has previously been determined that IP-
10 consists of three anti-parallel b-sheets overlayed by an a-helix at
the C-terminus [11]. The N-loop region of the b-sheets has been
suggested to play a role in the binding of the protein to the
receptor [12], but the domain responsible for receptor-activation is
not well understood. As such, we sought to identify the functional
domain of IP-10 that is responsible for CXCR3B activation and
the resulting inhibition of endothelial cell function. We identified
by homology modeling a 22 amino acid peptide spanning the a-
helical domain of IP-10, residues 77–98, which has the ability to
activate CXCR3B. We show that IP-10p is able to inhibit
endothelial cell motility, vessel formation and induce vessel
dissociation. In this study, we demonstrate that the a-helix domain
of IP-10 is able to inhibit endothelial cell motility, vessel formation
and induce vessel dissociation via direct binding and activation of
the CXCR3B receptor.
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Results
Synthetic IP-10p Binds to Endothelial Cells
We were looking to identify a small peptide agonist that would
activate CXCR3B. This will have a distinct advantage over the
large and labile natural peptides in production and stability. To
identify the active region of IP-10 that is required for the activation
of CXCR3, we analyzed the protein sequence for properties
similar to other known angiostatic molecules. Our initial search
was based on lytic peptides, which are small basic proteins of 23–
39 amino acids that have the potential to form amphipathic a-
helices or partial b-pleated sheets. These small oligo peptides have
been shown to interact with various membrane receptors. Using
this as the modality for our analysis, we identified the a-helical
region of IP-10 as a possible agonist for CXCR3 (Figure 1). The
peptide identified spans the C-terminal 22 amino acid residues 77–
98 that encompasses the a-helix (Accession# P02778) [13]. To
determine whether IP10p binds to CXCR3 on human dermal
microvascular endothelial cells (HMEC-1) [4], we analyzed the
ability of Biotin-tagged IP-10 and IP10p to compete for binding to
human microvascular endothelial cells HMEC-1 using flow
cytometery. We tested whether IP-10p binds to HMEC-1 cells.
While this data cannot determine the affinity of IP10p for
CXCR3, it does show that IP10p effectively binds to endothelial
cells (Figure 2A). Motility assay was performed to determine the
biological effects of biotinylation activity of IP-10 and IP-10p using
the optimal concentration determined in Figure 3A. Endothelial
cell migration was inhibited by biotinylated IP-10 and IP-10p as
expected (Figure 2B). As such, to show that IP-10p actually binds
to CXCR3 we performed a competition assay with IP-10.
To perform the competition assay we first needed to determine
a suboptimal amount of IP-10p that significantly labels the cell. A
saturation assay was performed by incubating fixed cells with six
increasing doses of biotin labeled peptide as indicated in the
methods. Cells were robustly washed free of unbound labeled IP-
10p and stained with FITC conjugated Strepavidin. Cells were
analyzed by flow cytometry and the mean fluorescence intensity
(MFI) obtained. All incubations and washes were performed at
4uC to minimize internalization. Figure 2C shows that increasing
MFI was obtained with increasing concentration of biotin labeled
IP-10p and saturability was observed above 4 mM (10 mg/ml) of
labeled IP-10p. Based on these results all the competition assays
were performed with the sub-optimal concentration of labeled IP-
10p at 4 mM.
In the first competition assay, the specificity of binding of the
biotin labeled IP-10p to endothelial cells was assessed by
competition with increasing concentrations of unlabeled IP-10p.
A fixed number of endothelial cells were co-incubated with 1 mg/
ml biotin labeled IP-10p and increasing concentrations of
unlabeled IP-10p as indicated on the x-axis of the graph
(Figure 2D). Cell were washed and stained with Strepavidin-FITC
and analyzed by flow cytometry. As shown in Figure 2C unlabeled
IP-10p was able to compete away the signal demonstrating the
specificity of the binding of IP-10p to endothelial cells. To verify
specificity of IP-10p, an unlabeled 22 amino acid scrambled
peptide failed to inhibit IP-10p binding to endothelial cells.
In the second competition assay, we determined whether IP-10p
bound to the same receptor as IP-10. A fixed number of
endothelial cells were co-incubated with 1ug/ml biotin labeled
IP-10 peptide and increasing concentration of unlabeled IP-10 as
indicated on the x-axis of the graph (Figure 2E). Cells were washed
and stained with Strepavidin-FITC and analyzed by flow
cytometry. Unlabeled IP-10 was able to prevent IP-10p binding
to endothelial cells indicating that IP-10p binds to the same
receptor on endothelial cells. As CXCR3 is the sole receptor for
IP-10, these data indicate that IP-10p also binds to CXCR3.
IP-10p Inhibits Endothelial Cell Motility
IP-10 inhibits human microvascular endothelial cells (HMEC-1)
motility in the presence of angiogenic growth factors VEGF165 and
bFGF (data not shown). [7,14–16] To examine whether IP10p
could mimic the inhibitory effect of the full length IP-10, HMEC-1
were analyzed using a scratch assay. Cells were tested for their
ability to migrate into a denuded area over a 24-hour period in the
presence or absence of VEGF165. Treatment with IP-10p
significantly inhibited HMEC-1 cell migration in the absence or
Figure 1. Structure model of IP-10 and IP-10p. Full Length Sequence of IP-10 with C-terminal 22 amino acids highlighted comprising IP-10p.
doi:10.1371/journal.pone.0040812.g001
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presence of VEGF (Figure 3). Figure 3A shows the dose response
used to determine the optimal concentration of IP-10p used. IP-
10p (10 mM) was found to inhibit endothelial cell migration to the
same degree as IP-10 (Figure 3B). Scrambled control peptide was
used at 10 mM and showed no such inhibition. These data
demonstrate that IP-10p is functional and is at least equivalent in
effect to IP-10 in cell motility inhibition.
Endothelial Tube Formation is Inhibited by the IP-10p
ELR-negative chemokines have been shown to limit vascular-
ization by regulating endothelial cells ability to form tubes in vitro
(6,7,10). To determine whether the IP-10p is able to inhibit tube
formation, HMEC-1 cells were grown on growth factor reduced
(GFR) Matrigel in the presence of VEGF165, IP-10 or IP-10p.
Figure 4A shows the dose response used to determine the optimal
concentration of IP-10p used. After incubation for 24 hours, the
cells were able to form tubes in the presence or absence of
VEGF165. When HMEC-1 cells were incubated with IP-10p, there
was a significant reduction in tubes formed compared to
scrambled control and even regardless of the presence of VEGF165
(Figure 4B). Quantification of tube formation demonstrates IP-10p
was able to reduce tube formation slightly better than that
observed for full length IP-10, in the presence of VEGF
(Figure 4C).
IP-10p Induces Tube Dissociation
IP-10 not only inhibits cells migration and tube formation, but
also drives involution of nascent vessels [7,10]. Thus, we
determined whether IP-10p also induces dissociation of newly
formed tubes. Using the Matrigel assay in vitro, HMEC-1 cells were
plated on GFR-Matrigel for 24 hours to allow the formation of
tubes. The medium was removed and replaced with medium
containing VEGF and molar equivalent IP-10 or IP-10p then
incubated for another 24 hours. After 48 hours, tubes were still
present in the controls treated with VEGF alone (Figure 5).
Figure 5A shows the dose response used to determine the optimal
concentration IP-10p used. With IP-10p treatment, there was a
significant reduction in the number of tubes observed compared to
control, VEGF (Figure 5A & B). The reduction of the number of
tubes was equivalent to treatment with IP-10.
IP-10p Signal through CXCR3
The inhibitory effects of IP-10 on endothelial cells has been
shown to be meditated via CXCR3 signaling. To determine if IP-
10p is acting through the same signaling pathways, we used a
CXCR3 neutralizing antibody and assessed the ability of IP-10p to
block tube formation as shown in Figure 5. HMEC-1 cells were
grown on growth factor reduced Matrigel in the presence of
VEGF and molar equivalent IP-10 or IP-10p, and with the
presence or absence anti-CXCR3 blocking antibody. After 24
hours on growth factor reduced Matrigel, HMEC-1 cells were able
to form tubes in the presence or absence of VEGF. As expected,
incubation with VEGF showed a significant enhancement in the
number of tubes formed compared to the untreated cells
(Figure 6A and 6B). When HMEC-1 cells were incubated with
IP-10p in the presence of the anti-CXCR3 antibody, the
inhibitory effect of IP-10p was reversed. IP-10p was unable to
override the angiogenic signals from VEGF, and limit tube
formation in the presence of VEGF when CXCR3 receptor was
neutralized (Figure 6A and 6B). A similar observation was made
when IP-10p was replaced with IP-10. These data strongly suggest
that the IP-10p inhibitory effect on endothelial cells is CXCR3-
mediated.
To further verify that the inhibitory effect of IP-10p is mediated
through CXCR3, HMEC-1 were treated with CXCR3 specific
siRNA and then incubated on GFR-Matrigel in the presence of
IP-10p. The tube density of the siRNA-mediated knockdown cells
was similar to non-specific siRNA treated cells and untreated
HMEC-1 cells incubated in the absence of IP-10p (data not
shown). When the endothelial cells were transfected with CXCR3
siRNA neither IP-10 nor IP-10p inhibited tube formation in the
absence or presence of VEGF (Figure 6C). This CXCR3-
dependence was also noted for endothelial cell migration; IP-10p
did not inhibit endothelial migration of CXCR3 siRNA-treated
cells into the denuded space. In comparison, IP-10p did inhibit cell
migration of the CXCR3 siRNA transfected cells (Figure 6D).
Knockdown of CXCR3 in these cells was verified by immuno-
staining for CXCR3. The CXCR3 siRNA treated cells showed a
significant reduction in CXCR3 staining, where as the cells
transfected with scramble siRNA (control) stain positive for
CXCR3 (Figure 6E). Together these data show the inhibitory
effects on both VEGF induced tube formation and cell migration
are due to IP-10p mediated activation of CXCR3.
In endothelial cells and fibroblasts, IP-10 mediated signaling is
through CXCR3 and has been shown to induce cAMP activation
of PKA and is required for inhibiting tube formation and motility
[7,8]. In contrast, cAMP is not increased when keratinocytes are
exposed to IP-10 resulting in motogeniesis [17,18]. As such, to
determine if stimulation of endothelial cells with IP-10p induces an
increase in cAMP, HMEC-1 cells were incubated with VEGF in
the presence or absence IP-10 or IP-10p. Forskolin was used as a
control. Cells were then assayed for total cAMP production.
Treatment of HMEC-1 cells with IP-10p showed a 2-3-fold
increase in cAMP production compared to untreated and VEGF
treated cells (Figure 7A). When the cells were stimulated with a
combination of VEGF and IP-10p, there was still a significant
increase in cAMP production compared to VEGF alone. These
results indicate that incubation of endothelial cells with IP-10p
induces the formation of cAMP.
Protein Kinase A (PKA), a cAMP-dependent kinase, has been
previously shown to be an inhibitor of endothelial cell migration
and tube formation [7,19]. Herein we sought to determine if the
increase in cAMP in endothelial cells by the induction of IP-10p
results in the activation of PKA. HMEC-1 cells were treated with
VEGF, IP-10, IP-10p alone or in various combinations. Using a
non-radioactive detection assay, total phosphorylated protein was
quantified by spectrophotometry. Incubation of HMEC-1 cells
Figure 2. Binding of IP-10p to HMEC cells occurs via CXCR3. A) Biotin tagged IP-10 and IP-10p were incubated with cells and then probed
with FITC-conjugated with streptavidin and analyzed on a BD FACSCalbur flow cytometer. Control cells were incubated with FITC-Streptavidin alone.
Motility analysis shows the effects of biotinylated IP-10 (23.2 mM), IP-10p (10 mM) C) Binding of IP-10p to endothelial cells is saturable. Endothelial cells
were incubated with increasing doses of IP-10p as indicated. Cells were extensively washed in PBS with FITC-Streptavidin analyzed by flow cytometry.
Mean fluorescent intensities of labeled cells are plotted against the concentrations of IP-10p. D) IP-10p binds specifically to endothelial cells.
Endothelial cell were incubated with 1ug/ml biotin labeled IP-10p and increasing control of unlabeled IP-10p or scrambled control at peptide. Cells
were stained with FITC-Streptavidin analyzed by flow cytometry. (mg unlabeled IP-10p n unlabeled scrambled peptide) E) IP-10 competes with IP-10p
for binding. Endothelial cells were incubated with 1ug/ml biotin labeled IP-10p and IP-10. Cells were stained with FITC-Streptavidin analyzed by flow
cytometry. Mean fluorescent intensities are plotted as a function of increasing quantities of competitor proteins. Data shown are of N= 6.
doi:10.1371/journal.pone.0040812.g002
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with IP-10p showed a significant increase in PKA activity in
comparison to VEGF and untreated cells (Figure 7B). These
results suggest that IP-10p activates PKA.
In endothelial cells, the CXCR3-activation of PKA inhibits
motility through inhibition of m-calpain (CAPN2) [7]. Recently, it
has been established that VEGF induces m-calpain activity in
endothelial cells. In endothelial cells, and in other cells m-calpain
Figure 3. 2D scratch assay of stimulated HMEC-1 cells was used to analyze migration patterns. A) The dose response used to determine
the optimal concentration IP-10p (10 mM) used to compare to IP-10 (34.9 mM) B) HMEC-1 cells were grown to 80 to 85% confluence in a 12-well plate
and quiesced in 0.5% dialyzed fetal bovine serum for 24 hours. A 1-mm scratch was made to the confluent of monolayer using a rubber policeman.
The cells were then incubated in 0.5% dialyzed with/without IP-10 (23.2 mM), IP-10p (10 mM), VEGF (3.9 mM) or and/or scrambled control (10 mM) for
24 hours. As expected, IP-10p inhibited motility of the HMEC-1 as wells as inhibited VEGF induced motility. The results are N= 6 (average 6SEM).
*P,0.05.
doi:10.1371/journal.pone.0040812.g003
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Figure 4. IP-10p is able to inhibit tube formation. A) The dose response used to determine the optimal concentration IP-10p (10 mM) used to
compare to IP-10 (34.9 mM). B) HMEC-1 cells were grown, detached and resuspended in serum-free medium either with or without VEGF (3.9 mM), IP-
10 (34.9 mM), IP-10p (10 mM) and/or scrambled control (10 mM) for 24 hours. Treated cells (1 x104 cells/well) were added to 24-well culture plates
coated with growth factor reduced Matrigel and incubated for 24 hours. C) Newly formed endothelial tubes in A were analyzed and quantified using
MetaMorph image programming. Data shown are of N= 6 and normalized to no treatment (average 6SEM). *P,0.05. Original magnifications, 4X.
doi:10.1371/journal.pone.0040812.g004
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(CAPN1) is activated secondary to a calcium flux [17] whereas m-
calpain is activated, at least in part, by ERK phosphorylation on
serine 50. We tested the IP-10p effect on m-calpain by using
membrane permeable synthetic calpain substrate Boc-LM-
CMAC. Keeping in mind that the pre-fluorescent substrate Boc-
LM-CMAC can be cleaved by both m- and m-calpain, we used
BAPTA/AM, a membrane permeable calcium chelator, to
distinguish between m- and m-calpain activation in cells, as this
blocks activation of m-calpain but not m-calpain [10,17]. Cells
were treated with VEGF in the presence of IP-10 and/or IP-10p
so cleavage of Boc-LM-CMAC was observed by the presence of
fluorescence. When the cells were pre-incubated with BAPTA/
AM, which was similarly extinguished by IP-10 and IP-10p,
comparable results are observed (Figure 7C). These results were
quantified to show total cells per field (Figure D). These data
suggest that the IP-10p inhibits VEGF mediated m-calpain
activity.
IP-10 Peptide Inhibits the Formation of New Vessels and
Causes the Dissociation of Newly Formed Vessels
Thus far we have demonstrated that IP-10p is able to inhibit
endothelial tube formation and induce the dissociation of formed
tubes in vitro. To determine whether IP-10p is able to inhibit
vessel growth, an in vivo Matrigel assay was used to determine
whether IP-10p is able to inhibit angiogenesis. GFR-Matrigel
supplemented with VEGF165 only was injected into one side of
the inguinal region of mice. The other side was injected with
Matrigel containing VEGF and IP-10p. The matrigel was
incubated for 10 days to allow vessel invasion into the Matrigel.
The Matrigel plug was removed and examined histologically
using Masson’s trichrome staining. The staining showed that
while VEGF induced endothelial invasion and formation of
vessels, IP-10p inhibited this angiogenesis in the presence of
VEGF (Figure 8A). These vessels were quantified and revealed
the IP-10p inhibition. These results indicate that IP-10p has the
ability to inhibit VEGF-induced vessel formation. In addition, it
has been previously shown that IP-10 can mediate vessel
regression of newly formed vessels in vivo [10]. To test whether
the IP-10p could mediate the same regression in an in vivo
environment, Matrigel containing VEGF was injected into the
subcutaneous space of mice. On day 10 vessels were observed in
the matrigel (Figure 8B, VEGF Day 10). On days 10 and 12 one
side of the inguinal region was inoculated with saline and the
other with IP-10p. At day 17 post Matrigel injections, the
implanted Matrigel plugs were removed and analyzed for vessel
formation. Our findings show that IP-10p treatment causes the
dissociation of newly formed vessels (Figure 8B, IP-10p day 17).
The vessel dissociation incurred by IP-10p was similar to that
observed with IP-10 (Figure 8B, IP-10p day 17 and IP-10 day
17). Vessel dissociation was not due to a lack of trophic factors to
the matrigel as the day 17 saline-treated Matrigel showed an
increase in vascular density compared to day 10 (Figure 8B). The
plugs were stained with CD31 to validate endothelial cells
immigration into the plug (Figure 8C). Additionally, the plugs
were stained with desmin marker of vessel maturation. The
staining shows less mature vessels in the presence of IP-10p.
These data indicate that IP-10p is able to promote the
dissociation of newly formed vessels.
Discussion
Angiogenesis is modulated by chemokines secondary to their
influence on endothelial cell migration, proliferation, and survival
[20]. Thus, harnessing the effects of a key chemokine, would
provide an entre´e to control of pathological vessel growth. IP-10
(CXCL10), a chemokine secreted by a diverse range of tissues and
highly expressed in a wide variety of diseases, is known to be
angiogenic. Previously, we have reported that by binding to
CXCR3 on endothelial cells IP-10 can limit new vessel growth by
inhibiting endothelial cell migration [7], and induce involution of
new vessels by triggering endothelial cell anoikis [10]. It needs to
be noted that IP-10 does not block the motility of keratinocytes,
but rather increases their motility [15]. This is explained by the
diverse modulation occurring via the activation of two separate
downstream pathways from CXCR3 [7,21,22]. However, what is
significant is that the effect on endothelial cells and angiogenesis is
consistent in vitro and in vivo, and thus can be utilized to limit new
vessel growth.
CXCR3 is a seven transmembrane G-protein receptor that exist
as two variants called CXCR3-A and CXCR3-B. It has been
shown that CXCR3-A promotes chemotaxis and cell proliferation
while CXCR3-B stimulates signals for growth inhibition [23]. In
recent reports, CXCR3 signaling results in chemotactic activation
of keratinocytes via a PLCb pathway that induces m-calpain
activation, which is mediated by calcium influx. Whereas in
endothelial cells, chemotaxis is blocked via the inhibition of m-
calpain by a cAMP-PKA mediated pathway [7]. Therefore, it is
suggested that the regulation of these very different cellular
responses is due to CXCR3-A/B binding of chemokines.
As structure dictates function, the structural details of IP-10s are
fundamental to understanding IP-10-mediated processes via
CXCR3, and to develop CXCR3-targeted therapeutics. Herein
we sought to, and now report, epitopes that are at least in part
responsible for the inhibition of chemotaxis and calcium influx in
endothelial cells. Prototypical of CXC chemokine topology IP-10
secondary structure consists of an elongated N terminus that
precedes the first cysteine, followed by a region of the structure
which is between the second cysteine and the 310 helix known as
the N loop. This single-turn 310 helix is succeeded by three b-
strands and a C-terminal a-helix [11,24]. Previously peptides have
been developed that correspond with the b-strands, particularly b-
strand 1, which have been identified as the binding site responsible
for receptor-mediated chemotaxis and calcium flux [11]. To
determine the region of IP-10 that is responsible for the inhibitory
function in endothelial cells and results in an antiangiogenic
biological function, we synthesized a peptide corresponding to the
C-terminal a-helix region of IP-10 (IP-10p).
In this study, we investigated the antiangiogenic activities of IP-
10p. We provide evidence that the a-helix region of IP-10 (IP-10p)
is able to inhibit angiogenesis and cause the regression of newly
formed vessels. Our results show that IP-10p binds and signals via
the CXCR3 receptor. Further investigation is necessary to address
the question of the affinity by which IP-10p binds to CXCR3.
However, IP-10p stimulation of microvascular endothelial cells
Figure 5. IP-10p induces dissociation of newly formed tubes. A) The dose response used to determine the optimal concentration IP-10p
(10 mM) used to compare to IP-10 (34.9 mM). B) HMEC-1 cells were treated with VEGF (3.9 mM) and plated on GFR-Matrigel to form endothelial tubes.
The newly formed tubes were incubated in 0.5% dialyzed FBS medium for 24 hours with VEGF (48 hours) in the presence of IP-10 (34.9 mM)
(24 hrs+IP-10), or IP-10p (10 mM) (24 hrs+IP-10). C) Quantification of the endothelial tube area was determined, using MetaMorph. Data shown are of
at least N= 6 and normalized to no treatment (average 6SEM). *P,0.05. Original magnifications, 4X.
doi:10.1371/journal.pone.0040812.g005
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promotes the activation of PKA by increasing levels of cAMP
resulting in the inhibition of endothelial cell migration to a degree
comparable to the full length IP-10. It has been well established
that m-calpain induced motility is growth factor mediated [16].
Vascular endothelial growth factor (VEGF) stimulation of
endothelial cell motility, tube formation in vitro, and the growth
of newly formed vessel formation in vivo are mediated by its
activation of m-calpain via PKA activation. To determine the
ability of IP-10p to block the effects of VEGF induced m-calpain
activity, we analyzed its ability to activate PKA. Treatment of
endothelial cells with the IP-10p resulted in high levels of cAMP,
thus stimulating PKA, an inhibitor of endothelial function. This
novel PKA mediated pathway induced by IP-10 signaling has been
shown to regulate angiogenesis by stalling endothelial cell
migration [7]. Our data shows that IP-10p is able to signal in
the same fashion, which results in comparable inhibition. These
results were observed in our in vitro system and in vivo model. Most
importantly, IP-10p, similarly to the native chemokine, was able to
induce involution of nascent vessels. Furthermore, our current
studies show that IP-10p exerts a dominant affect on VEGF and
other pro-angiogenic factors. Though these are preliminary studies
requiring validation in models of pathological angiogenesis, our
data provides strong evidence for the novelty of IP-10p and its
ability to be an antiangiogenic inhibitor by controlling key
components in vascular regression.
In summary, the data obtained in vitro and in vivo have
demonstrated the efficacy of using IP-10p as a possible therapeutic
target for numerous pathological conditions that results in
uncontrollable angiogenesis. While containing only 22 amino
acids rather than the full 98 (accession P02778), IP-10p is
biologically comparable to the full length IP-10. More in-depth
studies are necessary to further define the underlying molecular
mechanism(s) through which IP-10p exerts its antiangiogenic
activity. However, IP-10p is a promising candidate as an
antiangiogenic treatment because of its small size and inhibitory
functions at low doses. Equally important, this small active
fragment may be useful in increasing bioavailability and enhanc-
ing therapeutic value through its combined use with engineered
agents or in nanotechnology-directed therapies.
Materials and Methods
Peptide
The peptide was synthesized using fMoc chemistry by
Polypeptide Laboratories in San Diego, CA. The IP-10 peptide
purification was conducted utilizing a Beckman HPLC fitted with
a YMC C18, 4.66250 mm column at 60uC. The solvent system
was: A= 0.1%TFA/H20, B= 0.1%TFA/ACN at a flow rate of
1 ml/min. Purity was determined using a LC/MS Finnigan
MAT-LC/Q. This peptide was chemically synthesized and
purified by HPLC, and the purity, relative mass, and sequence
was confirmed (data not shown). All peptides used where diluted in
culture medium to neutralize the TFA before use.
Cell Culture
Immortalized human microvascular cell line (HMEC-1; Pas-
sages 21–25) was used in all experiments. The HMEC-1 line was
obtained from the Center for Disease Control (Atlanta, GA) and
grown in 10% FBS-MDCB 131 medium (Gibco, Gaithersburgh,
MD) supplemented with 10 mM L-Glutamate (Gibco), 1 ng/ml
EGF (BD Biosciences, Bedford, MA), 1 mg/ml hydrocortisone
(Sigma, St. Louis, MO). Down regulation of CXCR3 using
siRNA: HMEC-1 cells were plated at 5.56105 cells/60 mm dish
and incubated overnight. The cells were 90–95% confluent. Cells
were transfected with 4 mM siRNA (2 mM Sigma, 2 mM Santa
Cruz) using Dharamacon #4 transfection reagent. The cells were
incubated for 24 hours, then placed in EGM-2MV medium for 48
hours and subsequently transfected as indicated above. After 48
hours of incubation in EGM-2MV medium, the cells were then
used for experimentation.
Biotin Labeling, Binding and Competition Assay
Sulfo-NHS-LC-Biotin (Thermo Scientific 21327) was prepared
to result in a 10 mM solution of Biotin. IP-10, IP-10p or anti-
CXCR3 neutralizing antibody was dissolved in PBS and
incubated with the biotin for 2 hours according to manufacturer’s
protocol. IP10p contains 5 lysines while IP-10 has 10 lysines within
its amino acid sequence and so there is a potential for a 2-fold
difference in bound biotin. However, measurement of bound
biotin as described in the manufacturer’s protocol revealed that
only 2 biotin were bound. For binding and competition cells were
suspended in PBS and Biotin label peptide or protein was added
for 30 minutes. Cells were then washed to remove unbound
peptide/protein and incubated with streptavidin conjugated with
FITC, re-washed and analyzed on a BD FACSCalbur flow
cytometer.
Cell signaling assays were carried out using HMEC-1 FITC
labeled peptide described above. Cells were analyzed by flow
cytometry to obtain the mean fluorescence intensity. Flow
cytometry was performed on a BD FACSCalbur flow cytometer.
Motility Assay
Cell migration was performed by plating HMEC-1 cells at
2.56105 cells/well in 12 well culture plates in complete growth
medium and incubated for 24 hours at 37u in 5% CO2. The cells
were washed one time with PBS and then incubated in 0.5%
dialyzed MDCB 131 medium for 24 hours at 37uC in 5% CO2.
The monolayer was scraped with a rubber policeman making a
1 mm wide denuded area. The cells were then stimulated with or
without IP-10 (34.9 mM), IP-10p (10 mM), VEGF (3.9 mM), anti-
CXCR3 neutralizing antibody and in combination for 24 hours at
37uC in 5% CO2. Images were taken at time zero and 24 hours,
and the relative distance traveled by the cells into the acellular area
was determined using MetaMorph.
Figure 6. CXCR3 neutralizing antibody blocks IP-10p inhibition affects. A) HMEC-1 cells were grown, detached and resuspended in serum-
free medium and pretreated with a neutralizing antibody to CXCR3 (0.5 mg/ml) 30 minutes prior to addition to VEGF (3.9 mM), IP-10 (34.9 mM), IP-10p
(10 mM) and/or IgG (control). Treated cells (1 X104 cells/well) were added to 24-well culture plates coated with growth factor reduce Matrigel and
incubated for 24 hours. Endothelial tubes were allowed to form. B) Quantification of the endothelial tube was done using MetaMorph C) CXCR3 siRNA
down regulation of CXCR3 was used on the HMEC-1 cells and incubated on GFR-Matrigel in the presence of IP-10 VEGF (3.9 mM), IP-10 (34.9 mM) and/
or IP-10p (10 mM). Quantification of the endothelial cell tube density was shown using MetaMorph analysis. D) To demonstrate that the IP-10p
inhibition of motility is mediated via CXCR3, a siRNA down regulation of CXCR3 was used on the HMEC-1 cells. The 2-D scratch assay was performed
on the CXCR3 knockdown cells under the same condition above. Both IP-10 and IP-10p were unable to block VEGF induced motility. E)
Immunofluorescence staining to verify siRNA knockdown of CXCR3. Data shown are of N= 6 and normalized to no treatment (average 6SEM).
*P,0.05. Original magnifications, 4X.
doi:10.1371/journal.pone.0040812.g006
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Tube Formation Assay
Growth factor reduced (GFR) Matrigel 10 ml/well (in 15-well
m-angiogenesis slides, ibidi, Germany), was incubated for 15
minutes at 37uC. HMEC-1 cells (10,000 cells/well) were
resuspended in 0.5% FBS MDCB131 medium containing
VEGF (3.9 mM), IP-10 (34.9 mM) and IP-10p (10 mM) and or
anti-CXCR3 neutralizing antibody as described in the figure
legend. The cells were plated on the Matrigel and incubated for
24 hours at 37uC to allow tube formation. For the tube
dissociation assay, HMEC-1 cells were resuspended in 0.5%
FBS MCDB131 medium containing VEGF (3.9 mM) and
incubated on GFR-Matrigel for 24 hours at 37uC to allow
tube formation. The medium was removed and replaced with
0.5% FBS MCDB131 medium containing VEGF (3.9 mM), IP-
10 (34.9 mM) and IP-10p (10 mM) as indicated in the figure
legend then further incubated for 24 hours at 37uC in 5% CO2.
The cells were then imaged for tube formation using an
Olympus IX70 microscope equipped with a Hammastu camera
using MetaViewTM software (Universal Imaging Corporation,
Downington, PA). Analysis of tube formation was performed
using MetaMorph (Universal Imaging Corporation, Down-
ington, PA); and the results are shown as a percent of the
no-treatment control. Quantification of the tubes was performed
by taking six 4x images of each chamber, the tube formation
was assessed by area of each image and was analyzed by
MetaMorph and averaged together. The average tube formation
is represented at a percentage of the no treatment control (7).
cAMP Assay
HMEC-1 were plated in 10 mm culture dishes and grown to
confluency in complete growth medium. The cells were then
incubated in serum-reduced medium (0.5% dialyzed FBS for
HMEC-1 cells) for 24 hours at 37uC. The cells were then washed
once with PBS and incubated in serum-free medium. The cells
were then stimulated with forskolin (25 mM), VEGF (5.2 mM), IP-
10 (23.3 mM), IP-10p (10 mM) alone or in various combinations.
The medium was removed, ice cold 80% ethanol was added, and
the cells incubated on ice for 15 minutes. The extracts were
evaluated and quantified by using cAMP enzyme immunoassay kit
(Sigma, St. Louis, MO). The assay was performed according to
manufacturer’s protocol.
PKA Assay
HMEC-1 cells were grown in complete growth medium then
further incubated in 0.5% dialyzed FBS MCDB 131 medium for
24 hours. The cells were then stimulated with VEGF (5.2 mM)
and/or IP-10 (23.3 mM), IP-10p (10 mM) and in combination for
15, 30 and 60 minutes. The cells were lysed with an ice-cold
hypotonic solution (50 mM Tris pH 7.4, 1 mM EDTA, 10 mg/ml
aprotinin and 1 mM PMSF). The cells were incubated on ice for
30 minutes then centrifuged to remove the cell membranes. PKA
activity was measured using a cAMP dependent protein kinase kit
Non-Radioactive Detection kit (Promega). The assay was
performed according to manufacturer’s protocol.
Calpain Activation Assay
8-well chamber slides were coated with 0.1% gelatin for 24
hours at 4uC. The gelatin was removed and HMEC-1were
plated at 12,000 cells/well then incubated in 10% FBS-EBM-
EC medium for 24 hours. The medium was removed and the
cells were further incubated for 12 hours with 0.5% dialyzed
FBS-EBM medium. The cells were incubated with either
BAPTA AM (5 mM), or Calpain inhibitor I (CI-1, 10 mM) at
37uC for 30 minutes. BOC-LM-CMAC (Boc) (25 mM, Molec-
ular Probes) was added and incubated at 37uC for 30 minutes,
then VEGF (3.9 mM), IP-10 (23.3 mM), and IP-10p (10 mM) was
added and incubated for 30 minutes at 37uC. In some
experiments, the addition of cAMP analogs 8-Br-cAMP
(50 mM), activator of PKA, and Rp-8-Br-cAMP (250 mM),
inhibitor of PKA for 20 minutes prior to the addition of Boc.
The cells were then placed under a coverslip and analyzed for
cleavage of Boc by fluorescence microscopy. Quantification of
positive cells was performed by counting the total number of
cells and the fluorescent cells in a 46 image using MetaMorph.
The absence of fluorescent cells in the no treatment served as a
control. Digital images were captured using a Spot Flex digital
camera and Spot software.
siRNA Transfection
CXCR3 siRNA transfection was performed as previously
described. HMEC-1 cells were plated in a 6-well tissue culture
plate at 4.06105 cells/well in complete MCDB131 medium and
incubated overnight. The cells were ,75% confluent. The
medium was removed and replaced with serum free Opti-Mem
and incubated for 30 minutes. Dharmafect #4 was added to
Opti-Mem to a final concentration of 2.5% (final volume
200 ml) then incubated for 5 minutes at room temp. In parallel,
CXCR3 siRNA was diluted in Opti-Mem to a final concen-
tration of 200 mM (final volume 200 ml) then incubated for 5
minutes at room temp. CXCR3 siRNA was a pool of equal
concentration from Sigma and Santa Cruz. The Dharmafect
solution was added to the CXCR3 siRNA pool and incubated
for 20 minutes at room temp. The Dharmafect/siRNA solution
was diluted with 1.6 ml of complete MCDB131 medium, then
added to a well and incubated for 6 hours at 37uC with 5%
CO2. The medium was removed and replaced with complete
MCDB131 medium. Cells were incubated for 48 hours at 37uC
with 5% CO2. After 48 hours the cells were transfected a
second time as indicated above. The cells were incubated for 36
hours in complete MCDB131 medium at 37uC with 5% CO2
then detached for use. Staining for CXCR3 was using to detect
expression.
Figure 7. IP-10p induces cAMP activation of PKA. A) HMEC-1 cells were stimulated with 0.1% DMSO (no treatment) and/or with forskolin
(25 mM), VEGF (5.2 mM), IP-10 (23.3 mM), IP-10p (10 mM) in combination. Cell lysate was analyzed for total cAMP using cAMP enzyme immunoassay
kit. B) HMEC-1 were stimulated with VEGF (5.2 mM) and/or IP-10 (23.3 mM), IP-10p (10 mM) and in combination for 15, 30 and 60 minutes. The cells
were lysed in a hypotonic solution containing aprotinin and PMSF. The lysate was then analyzed for PKA activity using a PKA -assay kit (Promega) and
absorbance was read at 570 nm with the solubilization buffer serving as a blank. The graph shows the amount of the synthetic substrate
phosphorylated by PKA. C) HMEC-1 cells were plated on gelatin-coated glass chamber slides at 1.26104 cells/well and incubated for 24 hours and
then further incubated in 0.5% dialyzed fetal bovine serum for 24 hours. BAPTA AM (5 mM), or Calpain inhibitor I (CI-1, 10 mM) at 37uC for 30
minutes. The BOC-LM-CMAC (Boc) (25 mM,) was added and incubated at 37uC for 30 min, then VEGF (3.9 mM), IP-10 (23.3 mM), and IP-10p (10 mM) was
added and incubated for 30 minutes at 37uC. In some experiments the addition of cAMP analogs 8-Br-cAMP (50 mM), activator of PKA, and Rp-8-Br-
cAMP (250 mM), inhibitor of PKA for 20 minutes prior to the addition of Boc. Calpain activation was analyzed by fluorescence microscopy. D) Calpain
activity was quantified by MetaMorph analysis. Data shown are of at least N = 9 and normalized to no treatment (average 6SEM). *P,0.05. Original
magnifications, 10X.
doi:10.1371/journal.pone.0040812.g007
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Figure 8. IP-10p is able to inhibit angiogenesis. A) C57BL/6J mice were subcutaneously implanted with 750 ml of Matrigel containing VEGF
(23.3 mM), IP-10 (1.2 mM) and/or, of IP-10p (41 mM). Ten days post inoculation; the Matrigel plug was removed and stained with Masson Trichrome to
visualize endothelial infiltration. Vessels were quantified by counting vessel infiltration in to the plug on day 10. B) To verify that IP-10p is able to
inhibit regression of newly formed vessel in vivo GFR- Matrigel supplemented with VEGF (10.4 mM) was injected into both the left and right side groin
of mice. After 10 days the left side Matrigel plug was removed (control, n= 6) to show vessel invasion. The remaining right side Matrigel plug in the
mice was injected with either IP-10 (1.2 mM) and/or, IP-10p (41 mM) at days 10 and 12. Day 17, the Matrigel plugs were removed and stained with
Masson’s Trichrome. C) To validate the invasion of endothelial cells plugs were stained with CD31. IP-10p treated plugs showed a significant
regression of vessels compared to the saline controls. D) Vasculature is a marker of vessel maturation Desmin to validate mature vessels. Images
shown represent N= 8 Original magnifications, 10X and/or 40X.
doi:10.1371/journal.pone.0040812.g008
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In vivo Matrigel Plug Assay
Vessel regression in vivo was determined using the method
previously described (7). In brief, Matrigel (500 ml) with VEGF was
injected into the groin area near the dorsal midline of 12-month-
old C57B1/6 female mice. The mice were injected with 50 ml of
saline (control), 1.2 mM of IP-10 and/or 41 mM of IP-10p. On day
10 and 12 post Matrigel inoculation, the mice were injected in the
inguinal region. One side received saline, the other an equal
volume of IP-10 or IP-10p. Matrigel plugs were removed on day
10 (control for vessel invasion) and day 17 and either paraffin
embedded or flash frozen. Plugs were histologically analyzed for
vessels by Masson’s Trichrome. CD31 and Desmin (Abcam) were
used for staining of Matrigel plugs. Quantification was performed
MetaMorph and Image J software.
Statistical Analyses
All quantitative assays were performed at least six times each in
triplicate experiments. All animal assays were performed on a
minimum of six mice. Results are expressed as mean 6 SEM per
specimen or experiment because all individual assay measure-
ments were performed in replicate. Statistical differences between
groups were determined by using a two-tailed Student’s t-test.
Paired analyses were performed between all groups. Significance is
deemed at P,0.05.
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